Cover Image
市場調查報告書

EpiCast Report:黑色素瘤的流行病學的預測 (∼2023年)

EpiCast Report: Melanoma - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 331729
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:黑色素瘤的流行病學的預測 (∼2023年) EpiCast Report: Melanoma - Epidemiology Forecast to 2023
出版日期: 2015年04月06日 內容資訊: 英文 51 Pages
簡介

全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、澳洲) 的黑色素瘤的診斷病例數,預計從2013年到2023年以3.39%的年成長率推移,從2013年的155,057件至2023年達到207,606件。還有主要8個國家5年的累積患病人數,預計從2013年的639,165件到2023年擴大到860,889件。

本報告提供全球主要8個國家黑色素瘤的診斷病例數及死亡人數的變化的相關調查、疾病的背景、風險要素和並存症、各年齡、性別、重症度、原因病原的診斷病例數及死亡人數的預測等相關彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險要素與並存症
  • 全球趨勢
    • 美國
    • 歐盟5國
    • 日本、澳洲
  • 預測手法
    • 使用來源
    • 未使用來源
    • 預測的前提條件、手法
  • 黑色素瘤的流行病學預測
    • 診斷病例數
    • 診斷病例數:各年齡
    • 診斷病例數:性別
    • 標準診斷案例的比例:各年齡
    • 診斷的分期
    • 5年的患病人數
    • 5年的患病人數:遺傳基因異常
  • 檢驗
    • 流行病學的預測考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

目錄
Product Code: GDHCER078-15

Melanoma of the skin is a malignant neoplasm of melanocytes and is a significant source of morbidity and mortality worldwide.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of melanoma of the skin (all ages) in the 8MM will increase from 155,057 diagnosed prevalent cases in 2013 to 207,606 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 3.39%. The forecast shows an increase in the number of diagnosed incident cases of melanoma of the skin in all eight markets with AGRs ranging from 1.37% in Germany to 4.64% in the UK. In 2013, there were 639,165 five-year diagnosed prevalent cases of melanoma of the skin in the 8MM. GlobalData epidemiologists forecast that the five-year diagnosed prevalent cases of melanoma of the skin in the 8MM will increase to 860,889 diagnosed prevalent cases by 2023.

This forecast is based on a thorough literature review and is supported by 10 years of historical data from IARC's CI-5Plus database. The forecast for melanoma incident rates and diagnosed incident cases was based on detailed age-specific and sex-specific incidence trends in each of the 8MM from the CI-5Plus database published by the IARC of the WHO. GlobalData epidemiologists maintained consistent disease definition and forecasting methodology across all 8MM included in the report. In addition, GlobalData epidemiologists provided a comprehensive review of disease statistics and a realistic trend based on insights gained through research and analysis. GlobalData epidemiologists compared the diagnosed incident case estimates for melanoma from this forecast with the number of estimated incident cases from IARC's GLOBOCAN 2012 to assess the validity of GlobalData's epidemiological forecast and found the two to be in accordance.

Scope

  • The Melanoma EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for melanoma of the skin in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma of the skin, segmented by age (in 10-year age groups, beginning at 20 years and ending at =80 years), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] stages I, II, III, and IV). The forecast also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases and the five-year diagnosed prevalent cases segmented by genetic aberrations (BRAF and c-KIT) in these markets.
  • The melanoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global melanoma market.
  • Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for melanoma therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan and Australia
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Melanoma (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of Melanoma
    • 3.5.2. Age-Specific Diagnosed Incident Cases of Melanoma
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of Melanoma Skin Cancer
    • 3.5.4. Age-Standardized Diagnosed Incidence Rates
    • 3.5.5. Pathological Stage at Diagnosis
    • 3.5.6. Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer
    • 3.5.7. Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer by Genetic Aberrations
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Melanoma of the Skin
  • Table 2: Melanoma of the Skin Staging Definition Equivalencies
  • Table 3: 8MM, Sources of Melanoma of the Skin Incidence Data
  • Table 4: 8MM, Sources of Melanoma of the Skin Incident Cases by Pathological Stage at Diagnosis Data
  • Table 5: 8MM, Sources of Melanoma of the Skin Five-Year Diagnosed Prevalent Cases by Stage Data
  • Table 6: 8MM, Sources of Melanoma of the Skin Diagnosed Prevalent Cases by Genetic Aberration
  • Table 7: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, Ages ≥20 Years, N, Select Years 2013-2023
  • Table 8: 8MM, Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, N (Row%), 2013
  • Table 9: 8MM, Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin, Ages ≥20 Years, N (Row %), 2013
  • Table 10: Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ≥20 Years, 2013
  • Table 11: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, ≥20 years, N, Select Years 2013-2023

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 2: Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, N, 2013
  • Figure 3: Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin (N), 2013

Figure 4 : Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ≥20 Years, 2013 32

  • Figure 5: Distribution of Incident Cases of Melanoma Skin Cancer by Stage at Diagnosis (%)
  • Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 7: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with BRAF Mutations, Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 8: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with NRAS Mutations, Both Sexes, Ages ≥20 Years, 2013
Back to Top